Patient Medication Guide: How much does bosutinib cost per month?

Bosutinib (Bosutinib) is a newly approvedTKI for the treatment of adult patients with chromosome-positive chronic myelogenous leukemia (Ph+CML) who are resistant or intolerant to previous treatments. This drug is active against many mutations that are resistant to other TKIs, but is less active against the T315I and V299L mutations.

Bosutinib has activity againstSrc and Abl kinases and is more effective than imatinib. It has a different toxicity profile than imatinib, with a higher incidence of diarrhea, vomiting, and elevated transaminases. Long-term follow-up data are needed to determine duration of response, conversion rate to AP/BP-CML, and overall survival. Bosutinib is available in tablet form. It is only available by prescription, and treatment should be initiated by a doctor experienced in the diagnosis and treatment of chronic myelitis. The recommended dose is 400 mg once daily for newly diagnosed patients and 500 mg once daily for patients already receiving other medications. Doctors may increase the dose to 600 mg once daily or reduce or interrupt treatment based on the drug's effectiveness and the patient's side effects.

The originator drug of bosutinib is not marketed in the country, so it cannot be included in medical insurance. Currently, the original drugs sold overseas include Turkish version and European version. The price of Turkish version 500mg*28 per box may be more than 2,000 RMB, and the price of European version may be more than 30,000 RMB (the price may fluctuate due to the exchange rate). The price of one box may be needed for patients to use it for one month. There are also bosutinib generic drugs produced overseas in other countries. The ingredients are basically the same as those of the original drug. The price per box of 500mg*30 may be more than RMB 2,000 (the price may fluctuate due to exchange rates). The price for patients using it for one month will be cheaper than the original drug.